重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清LMTK-3、IGFBP-7 的影响

Effect of recombinant human endostatin plus chemotherapy on serum LMTK-3 and IGFBP-7 in patients with advanced non-small cell lung cancer

摘要:

目的 探讨重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清Lemur 酪氨酸激酶3（LMTK- 3）、胰岛素样生长因子结合蛋白7（IGFBP-7）的影响。方法 选取2012 年1 月-2015 年1 月于该院收治的 NSCLC 患者86 例为研究对象，按随机数字表法分为观察组和对照组，每组43 例。对照组患者采取吉西他滨+ 顺铂化疗。观察组在对照组基础上联合恩度治疗。对两组患者的临床疗效、不良反应、外周血血管内皮生长因 子（VEGF）、胰岛素样生长因子1（IGF-1）、LMTK-3、IGFBP 表达水平进行评价。结果 观察组治疗客观有 效率、总有效率高于对照组（P <0.05），观察组的疗效优于对照组，差异有统计学意义（P <0.05）。两组患者的 不良反应发生率并差异无统计学意义（P >0.05）。两组患者治疗后VEGF、IGF-1 及LMTK-3 水平较治疗前 更低，GFBP 水平较治疗后更高，差异有统计学意义（P <0.05），且观察组治疗后VEGF、IGF-1 及LMTK-3 水 平较对照组更低，IGFBP-7 更高，差异有统计学意义（P <0.05）。结论 重组人内皮抑素联合化疗可有效降低 NSCLC 患者的血清LMTK3 水平，升高血清IGFBO-7 水平，患者的疗效良好，不良反应较低。

Abstract:

Objective To investigate the effect of recombinant human endostatin combined with chemotherapy on serum LMTK-3 and IGFBP-7 in patients with advanced non-small cell lung cancer. Methods Totally 86 cases of patients diagnosed with advanced non-small cell lung cancer in our hospital from January 2012 to January 2015 were involved in this study. Patients were randomly divided into observation group and control group (n = 43). Patients from control group received gemcitabine + cisplatin chemotherapy. Patients from observation group received endostar in addition to standard treatment. The therapeutic efficacy, side effects and concentration of VEGF, IGF-1, LMTK-3 and IGFBP were recorded. Results The therapeutic efficacy in observation group was significantly higher than that of the control group (χ2 = 5.403, 7.493, P < 0.05). No statistically significant difference in the incidence of adverse events between the two groups was observed. The levels of VEGF, IGF-1 and LMTK-3 in both groups were significantly increased while GFBP decreased post treatments when compared with that prior to treatments (P < 0.05). Concentrations of VEGF, IGF-1 and LMTK-3 in observation group were downregulated while IGFBP-7 upregulated significantly when compared with control group (P < 0.05). Conclusion Recombinant human endostatin combined with chemotherapy is a promising option for treatment of NSCLC patients with good efficacy and less adverse reactions.